Pharming Group (NASDAQ:PHAR - Get Free Report) shares saw unusually-high trading volume on Monday . Approximately 5,632 shares changed hands during trading, a decline of 9% from the previous session's volume of 6,179 shares.The stock last traded at $8.39 and had previously closed at $8.65.
Wall Street Analysts Forecast Growth
Several equities analysts recently weighed in on the stock. Oppenheimer increased their price objective on shares of Pharming Group from $30.00 to $39.00 and gave the company an "outperform" rating in a report on Friday, March 14th. Jefferies Financial Group assumed coverage on shares of Pharming Group in a research report on Monday, December 9th. They set a "buy" rating and a $14.00 target price for the company. Finally, HC Wainwright restated a "buy" rating and issued a $37.00 price target on shares of Pharming Group in a research report on Thursday, March 20th.
Get Our Latest Research Report on Pharming Group
Pharming Group Stock Down 3.5 %
The firm has a market cap of $566.02 million, a P/E ratio of -32.00 and a beta of -0.10. The firm's 50 day moving average is $8.73 and its two-hundred day moving average is $8.69. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41.
Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.02). The firm had revenue of $92.70 million during the quarter, compared to analyst estimates of $76.67 million. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. As a group, research analysts anticipate that Pharming Group will post -0.2 EPS for the current fiscal year.
Institutional Investors Weigh In On Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its holdings in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 47,997 shares of the company's stock after purchasing an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 as of its most recent filing with the SEC. 0.03% of the stock is currently owned by hedge funds and other institutional investors.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Read More
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
